<DOC>
	<DOCNO>NCT01711775</DOCNO>
	<brief_summary>This single-center , non-randomized , open-label study ass pharmacokinetics aleglitazar administration single multiple oral dos healthy Chinese volunteer . Subjects receive single oral dose aleglitazar Day 1 repeat oral dos daily Day 5 Day 14 . Anticipated time study , include screen 2-week follow-up , 8 week .</brief_summary>
	<brief_title>A Pharmacokinetic Study Aleglitazar Healthy Chinese Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy female male Chinese volunteer , 18 45 year age inclusive screening Subjects healthy determine medical history , physical examination , vital sign , 12lead ECG , clinical laboratory measurement perform screen Body mass index ( BMI ) 19 24 kg/m2 inclusive Female subject surgically sterile must willing use effective method contraception define protocol throughout study 30 day last dosing Any significant allergic reaction multiple allergy Diagnosed treated malignancy ( except treat case basal skin cancer situ carcinoma cervix ) within past 5 year Any major illness within 2 month prior first dose febrile illness within 14 day prior first dose Positive hepatitis B , hepatitis C HIV infection Any clinically relevant history alcohol and/or substance abuse addiction within last 2 year Pregnant lactating woman , woman positive pregnancy test Regular smoker consumption 10 cigarette per day equivalent amount tobacco Participation investigational drug device study within 3 month prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>